City of Hope

Washington University

Yoko Fujita-Yamaguchi

Markus Kalkum

Karine Bagramyan

Teresa B Hong

Pierre DeMeyts

Sarah Shuck

David B Sacks

Jay M McDonald

Jean Smal

Disclosed herein are a recombinantS27S5 hemagglutinin (SHA), and homologues thereof, and a fusion protein of a fluorescent protein (such as GFP and mCherry1) and SHA or a homologue thereof, which specifically bind to carbohydrates, including oligomeric sugars that terminate in L-rhamnose or D-galactose. The SHA, SHA homologues, and fusion proteins can be used to detect a variety of microorganisms or cancer or tumor antigens.

Recombinant lectin and uses thereof

A method of inhibiting the growth of hormone dependent tumor cells in a mammal comprises administering to said mammal an insulin-like growth factor receptor (IGF-IR) recombinant antibody, wherein said antibody can be a single-chain recombinant antibody, which can be humanized, capable of blocking agonist interaction with the IGF-IR.

Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth

A method of activating human insulin receptor kinase and a method of reactivating human receptor kinase which has lost some, but not all, of its kinase activity, comprising reacting human insulin receptor with at least one basic protein.

Methods and compositions for activating the human insulin receptor kinase

A process which comprises administering an antagonist of protein kinase C and/or the insulin receptor tyrosine kinase to a mammal in an amount therapeutically effective to inhibit lipogenesis in the mammal.

Growing community of inventors

Glendora, CA, United States of America

Yoko Fujita-Yamaguchi